Login to Your Account



AB Science's Masitinib Enters Phase III Trial for Alzheimer's

By Catherine Shaffer
Staff Writer

Wednesday, May 22, 2013
AB Science SA, of Paris, began a Phase III trial of masitinib, a drug it already has studied broadly in cancer indications, in Alzheimer's disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription